Form 4: Stoke Therapeutics CEO Edward M. Kaye Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO Edward M. Kaye sold shares of Stoke Therapeutics to cover tax withholding liabilities related to the vesting of restricted stock units.
Summary
- On March 15, 2024, Edward M. Kaye, CEO of Stoke Therapeutics, exercised restricted stock units (RSUs) converting them into 35,500 shares of common stock.
- These shares were acquired at a price of $0.
- Simultaneously, 35,500 shares were sold to cover tax withholding liabilities associated with the vesting of these RSUs.
- On March 19, 2024, Kaye sold an additional 11,150 shares at a weighted average price of $6.0986, with prices ranging from $5.94 to $6.40.
- Following these transactions, Kaye directly owns 69,350 shares of Stoke Therapeutics common stock and 106,500 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, with no indication of significant positive or negative developments.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Sales to cover tax obligations related to vesting equity are typical and don't necessarily indicate a negative outlook on the company.
Stakeholder Impact
- The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Exercise of Restricted Stock Units and Sale of Shares for Tax Withholding |
| 03/19/2024 | Sale of additional shares |
| 03/15/2027 | Expiration date of Restricted Stock Units |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.